Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310449 | 1.00 | BCHE (0.54) | BCHEALDH1A1MAPK1LMNAGLA | |
| SCHEMBL4498148 | 1.00 | BCHE (0.54) | BCHEALDH1A1MAPK1LMNAGLA | |
| Hydrochloric Acid SCHEMBL6500960 | 0.98 | BCHE (0.53) | BCHEALDH1A1MAPK1LMNAGLA | |
| Trifluoroacetic Acid SCHEMBL30408658 | 0.88 | BCHE (0.46) | BCHEALDH1A1MAPK1LMNAGLA | |
| SCHEMBL2743262 | 0.87 | — | — | |
| SCHEMBL13748108 | 0.87 | — | — | |
| SCHEMBL12457873 | 0.87 | — | — | |
| SCHEMBL8439278 | 0.86 | ALDH1A1 (0.51) | BCHEALDH1A1MAPK1LMNAGLA | |
| SCHEMBL16377760 | 0.83 | SMN1; SMN2 (0.52) | BCHEALDH1A1MAPK1LMNAGAA | |
| SCHEMBL14500153 | 0.81 | ALDH1A1 (0.44) | BCHEALDH1A1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-20150011576-A1 | Inhibitors of Protein Kinases | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | claimed |
| US-8841315-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2014-09-23 | — | — | US | claimed |
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | claimed |
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-12 | — | — | US | claimed |
| EP-2627650-A2 | N-PHENYL IMIDAZOLE CARBOXAMIDE INHIBITORS OF 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | claimed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | claimed |
| US-8507511-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | claimed |
| US-8436007-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-05-07 | — | — | US | claimed |
| EP-2137165-B1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-04-24 | — | — | EP | claimed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | claimed |
| US-20070032492-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | claimed |
| EP-1567507-B1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331407-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK5 | BCHE 2960/4885ALDH1A1 4213/4885MAPK1 139/4885 |
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | BCHE 3258/4885ALDH1A1 3032/4885MAPK1 181/4885 |
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | BCHE 273/4885ALDH1A1 353/4885MAPK1 2180/4885 |
| US-20150011576-A1 | Inhibitors of Protein Kinases | CDK1, CDK2, CDK5 | BCHE 2960/4885ALDH1A1 4213/4885MAPK1 139/4885 |
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | BCHE 4290/4885ALDH1A1 272/4885MAPK1 315/4885 |
| US-20070032492-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1RN | BCHE 4264/4885ALDH1A1 281/4885MAPK1 295/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | BCHE 188/4885ALDH1A1 616/4885MAPK1 1239/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | BCHE 4122/4885ALDH1A1 3927/4885MAPK1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.